inflammatory bowel disease

inflammatory bowel disease
Name	Inflammatory bowel disease
Field	Gastroenterology
Symptoms	Abdominal pain; diarrhea; rectal bleeding; weight loss; fatigue
Complications	Bowel obstruction; colorectal cancer; fistula; malnutrition; extraintestinal manifestations
Onset	Any age, peak in adolescence and young adulthood
Duration	Chronic
Causes	Immune dysregulation; genetic susceptibility; environmental triggers; microbiome alterations
Diagnosis	Clinical assessment; endoscopy; histopathology; imaging
Treatment	Aminosalicylates; corticosteroids; immunomodulators; biologics; surgery

inflammatory bowel disease Inflammatory bowel disease (IBD) comprises chronic, relapsing inflammatory disorders of the gastrointestinal tract notable for persistent mucosal inflammation and systemic manifestations. It most commonly presents as Crohn disease or ulcerative colitis and requires coordination between clinical specialties, diagnostic modalities, and long-term therapeutic strategies.

Signs and symptoms

Patients often present with abdominal pain, chronic diarrhea, and rectal bleeding, accompanied by systemic features such as weight loss and fatigue. Multiple organ systems can be involved, producing dermatologic signs like erythema nodosum, ocular inflammation such as uveitis, and musculoskeletal complaints including peripheral arthritis; these extraintestinal manifestations link care across specialties and institutions such as Mayo Clinic, Mount Sinai Health System, Cleveland Clinic, Johns Hopkins Hospital, and Massachusetts General Hospital. Acute severe presentations may require hospitalization at tertiary centers like Royal Infirmary of Edinburgh or Karolinska University Hospital with complications including fever, tachycardia, and hypotension. Chronic disease courses vary from mild intermittent flares to continuous activity leading to strictures, fistulae, or perianal disease often managed at referral centers such as St Mark's Hospital or Addenbrooke's Hospital.

Causes and pathophysiology

IBD arises from a complex interplay of host genetics, immune dysregulation, environmental exposures, and microbiome disturbances. Genome-wide association studies involving consortia like the Wellcome Trust-funded projects and groups at Harvard Medical School and Broad Institute identified susceptibility loci including NOD2 and IL23R that implicate innate and adaptive immune pathways. Dysregulated cytokine signaling (for example, tumor necrosis factor and interleukin-12/23 pathways) has been characterized in translational research at institutions such as National Institutes of Health and Imperial College London, informing targeted biologic development by companies like AbbVie and Johnson & Johnson. Environmental risk modifiers include smoking, urbanization, antibiotic exposure, and diet patterns studied in cohorts from Framingham Heart Study-derived datasets and longitudinal registries maintained by European Crohn's and Colitis Organisation and Crohn's & Colitis Foundation. Perturbations of the gut microbiota, reported in studies from University of California, San Diego and Stanford University School of Medicine, show reduced diversity and altered composition, with research into fecal microbiota transplantation conducted at centers such as University Hospital Zurich.

Diagnosis

Diagnosis integrates clinical assessment, endoscopic visualization, histopathologic confirmation, laboratory testing, and imaging. Colonoscopy with biopsy, performed by specialists affiliated with hospitals like Guy's and St Thomas' NHS Foundation Trust and Hospital of the University of Pennsylvania, remains the cornerstone for distinguishing ulcerative colitis from Crohn disease. Cross-sectional imaging modalities including magnetic resonance enterography and computed tomography enterography are utilized at radiology departments in centers such as Mayo Clinic and University College London Hospitals. Serologic markers and fecal calprotectin measurements are used adjunctively in clinics influenced by guidelines from organizations like American Gastroenterological Association and British Society of Gastroenterology. Pathology interpretation often references classifications developed in academic centers such as Johns Hopkins University and University of Toronto.

Treatment and management

Therapeutic strategies combine induction of remission and maintenance therapy using aminosalicylates, corticosteroids, immunomodulators (azathioprine, methotrexate), and biologic agents targeting TNF, integrins, and interleukins; these regimens were developed and trialed in multicenter studies coordinated by groups like European Crohn's and Colitis Organisation and Crohn's & Colitis Foundation. Surgical interventions—resection, stricturoplasty, or proctocolectomy—are undertaken in specialist units such as Mount Sinai and St Mark's Hospital for complications or refractory disease. Nutritional therapies, including exclusive enteral nutrition protocols from institutions like Great Ormond Street Hospital and Boston Children's Hospital, play a role particularly in pediatric populations. Multidisciplinary care often involves colorectal surgeons, gastroenterologists, dietitians, and psychologists affiliated with academic centers like UCL and Columbia University Medical Center. Emerging therapies, including small molecules pioneered by pharmaceutical firms like Pfizer and stem cell transplantation studied at Mayo Clinic, are under active investigation.

Complications and prognosis

Complications include intestinal strictures, fistulae, perforation, hemorrhage, malabsorption, and increased colorectal cancer risk necessitating surveillance strategies recommended by societies such as American Cancer Society and European Society for Medical Oncology. Extraintestinal complications affect liver (primary sclerosing cholangitis), eyes, skin, and joints, requiring coordination with specialists at centers like Royal Free Hospital and John Radcliffe Hospital. Prognosis depends on disease subtype, extent, and response to therapy; long-term cohort data from registries at Karolinska Institutet and University of Copenhagen inform survival and surgery rates.

Epidemiology and risk factors

IBD incidence and prevalence vary globally, with rising rates in newly industrialized nations documented in epidemiologic work from China CDC, Indian Council of Medical Research, and Brazilian Ministry of Health. Historically higher burdens in North America and Europe have been reported by agencies including Centers for Disease Control and Prevention and Public Health England. Risk factors include genetic predisposition identified by consortia like the International IBD Genetics Consortium, smoking, appendectomy history, antibiotic exposure, and westernized diet patterns studied by research groups at University of Oxford and Yale School of Medicine. Age of onset commonly peaks in adolescence and early adulthood, with a second smaller peak later in life described in population studies from Danish National Patient Registry and Swedish National Board of Health and Welfare.

Category:Gastroenterology